Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each dropping 1.1%.
The iShares Biotechnology ETF (IBB) slipped 0.8%.
In corporate news, Eli Lilly's (LLY) weight loss drug Mounjaro will be rolled out initially to people with the highest clinical need in England over the next three years, according to the National Institute for Health and Care Excellence's draft guidance. Eli Lilly shares shed 0.5%.
Eli Lilly, Pfizer (PFE) and Pharmaceutical Research and Manufacturers of America executives dined with US President-elect Donald Trump on Wednesday night and held various discussions including potential public-private collaborations to find cures for cancer, Axios reported. Pfizer shares popped 2.2%.
Protara Therapeutics (TARA) shares surged past 75%. The company said its investigational therapy TARA-002 showed a complete response rate of 72% at six months in a phase 2 trial involving people with non-muscle invasive bladder cancer.
Novo Nordisk (NVO) said Thursday it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026. Its shares were 0.1% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.